Patients prescribed GLP-1 receptor agonists, such as semaglutide and tirzepatide, show a statistically significant decrease in daily physical activity after beginning treatment. Researchers from HSHS Saint John’s Hospital found that average daily step counts for users dropped from 5,047 to 4,487, while moderate-to-vigorous activity time declined by six minutes per day. These findings, scheduled for presentation at the Endocrine Society’s ENDO 2026 meeting, suggest that clinical weight loss management may require proactive exercise counseling to prevent potential muscle loss and metabolic decline.
Why Does Physical Activity Decline After Starting GLP-1s?
The reduction in physical activity among patients on medications like Ozempic or Wegovy appears linked to a shift in lifestyle habits following the rapid onset of weight loss. According to the study involving 753 volunteers from the All of Us research program, the decline was most pronounced in men and individuals experiencing musculoskeletal pain. Researchers hypothesize that as patients lose weight, they may perceive less need for movement, or they may struggle with energy levels as their caloric intake adjusts to the medication’s appetite-suppressing effects.
While exercise is not the primary driver of weight loss for most people, it remains the most effective tool for preserving lean body mass. Maintaining muscle strength is critical for long-term metabolic health, especially as patients shed fat mass alongside muscle tissue.
How Does This Compare to Clinical Expectations?
The findings from HSHS Saint John’s Hospital contrast with previous data from large-scale clinical trials. While the new research highlights a drop in activity, other studies cited by the Endocrine Society have suggested that physical functioning often improves as body weight decreases. This discrepancy creates a “GLP-1 paradox”: patients may feel physically lighter and more capable, yet their objective data—tracked via Fitbit devices—shows they are moving less.
| Metric | Pre-GLP-1 | Post-GLP-1 |
|---|---|---|
| Average Daily Steps | 5,047 | 4,487 |
| Moderate/Vigorous Activity | 28 minutes | 22 minutes |
What Are the Risks of Reduced Movement?
The primary concern regarding decreased activity is the loss of muscle mass. Although medications like semaglutide are highly effective for weight reduction, they do not distinguish between fat loss and lean tissue loss. According to the researchers, elderly patients are at a higher risk of complications from muscle loss, which can lead to reduced physical strength and diminished functional independence over time. Maintaining a consistent exercise routine acts as a buffer, ensuring that the weight lost is primarily fat rather than the muscle needed for daily physical functioning.
Pro Tips for Maintaining Fitness During Weight Loss
- Schedule Strength Training: Prioritize resistance exercises at least twice a week to signal the body to keep muscle tissue.
- Monitor Your Steps: Use wearable technology to track daily movement, aiming to maintain your pre-medication baseline.
- Address Pain Early: If musculoskeletal pain is hindering your ability to move, consult your physician about physical therapy options.
Frequently Asked Questions
Do GLP-1 drugs cause muscle loss?
The drugs themselves do not target muscle, but the rapid weight loss they induce can lead to a reduction in muscle mass if not paired with adequate protein intake and resistance exercise.
Is the decline in activity permanent?
The study is preliminary, and researchers suggest that targeted interventions, such as physician-led exercise counseling, can help patients maintain or increase their activity levels while on the medication.
Should I stop my medication if I am less active?
No. The researchers emphasize that these drugs remain highly effective for weight management. Instead, they recommend discussing an exercise plan with your doctor to support your overall health while using the medication.
Are you currently taking a GLP-1 medication? Share your experience with maintaining an exercise routine in the comments below, or subscribe to our newsletter for the latest updates on metabolic health and clinical research.
